Quince shed its founding A-T program and rebuilt entirely around inhaled rapamycin; the BOS readout is the first test of whether LAM-001 works in a controlled setting

Quince is a clinical-stage company developing LAM-001, an inhaled formulation of rapamycin, for bronchiolitis obliterans syndrome, a serious lung condition that is not yet approved with this drug.

Quince divested eDSP for $450,000 in September 2026 after the Phase 3 NEAT trial failed, making LAM-001, an inhaled rapamycin formulation, the entire company. Phase 2a PH-ILD data showed meaningful 6MWD and PVR improvements, but only four patients were evaluable, and no controlled efficacy data exist in any indication. The BOS readout and PH-ILD Phase 2b results are the only tests of whether LAM-001's early signals hold under rigorous conditions, with a crowded PH-ILD field including Liquidia's YUTREPIA as a direct competitor.